【ZiDongHua 之“方案应用场”栏目标注“第一对焦“、“自动对焦”关键词：三优生物 之江生物 新药研发 研发自动化 药物研发 智能自动化 】
三优生物与之江生物签订创新生物药自动化开发战略合作协议，协同攻关研发瓶颈，为创新药研发提供全新动能!
2025年10月29日，中国上海——三优生物医药(上海)有限公司(以下简称“三优生物”)与上海之江生物科技股份有限公司(以下简称“之江生物”)共同宣布，双方正式签署创新生物药自动化开发战略合作协议。此次合作旨在协同攻关药物研发瓶颈，通过引入自动化技术，大幅缩短创新药物的研发周期。
根据协议，三优生物将通过自动化升级开发流程，大幅缩短创新药物的研发周期。此次双方的战略合作，三优生物将系统性升级抗体药分子筛选工艺，从而解放科研人才双手，更专注于创造性分析工作。同时，更精准、稳定性强的自动化工艺也将极大提升研发预算的使用效率。
三优生物与之江生物此次战略合作的意义不仅在于“缩短研发周期”，更在于通过技术融合与战略协同，提升研发过程的确定性与成果产出效率、激发源头创新动力、重塑企业核心竞争力。双方的合作成果将进一步推动智能化医疗背景下的创新抗体药及诊疗技术发展，进一步惠及全球范围内相关的患者群体。
之江生物与三优生物签署战略合作协议
共同见证
此次合作将充分发挥三优生物全球领先的智能超万亿分子库(AI-STAL)技术和智能化药物筛选与临床前研究方面的优势，同时结合之江生物的自动化、智能化系统显著加快药物研发进程。
之江生物副总经理、董事会秘书
倪卫琴女士和三优生物CEO郎国竣博士
之江生物副总经理、董事会秘书倪卫琴女士表示：“我们期待通过这次合作，携手打破传统研发模式的壁垒，共同打造一个集‘自动化硬件’与‘AI智能决策’于一体的数智化新药研发新范式。我们的目标不仅是共同构建流程的‘高速公路’，更是借助人工智能与大数据分析，在靶点发现、分子设计等源头环节实现智能赋能与范式革新，全力加速创新药物从实验室到临床的转化进程，为人类健康事业贡献科技力量。”
三优生物创始人兼CEO郎国竣博士表示：“我们很高兴与之江生物正式达成战略合作。此次合作旨在以前沿创新思维破解生物药研发中的核心难题，通过三优的AI-STAL智能超万亿分子库和之江的自动化及智能化技术的深度融合，共同推动创新生物药研发关键技术的突破。双方优势互补，致力于构建更高效、更智能的研发体系，从而显著缩短药物研发周期，加速创新疗法上市进程，为全球患者带来更及时的治疗希望。”
本次战略合作内容包括联合研究、技术转移等多个方面。
关于之江生物
上海之江生物科技股份有限公司(证券代码：688317)是一家专业从事分子诊断试剂和仪器设备研发、生产和销售的国家高新技术企业，是国内技术先进、产品齐全的分子诊断领军企业。公司拥有80余项授权专利，获得国家技术发明奖二等奖等重大奖项10余项，承担国家级、省级重大科研项目40余项。在全球高致病性禽流感、埃博拉病毒、寨卡病毒等多次突发公共卫生事件中都有着突出表现，多款产品被WHO列入应急使用清单，获得权威认可。
公司全自动、智能化仪器与系统能够有效地解决国内传统分子诊断技术操作复杂、耗时长、自动化程度低、应用局限等行业难点，致力于成为全球分子诊断市场一体化解决方案的供应商。
关于三优生物
三优生物是一家以“让天下没有难做的创新生物药”为使命，以超万亿分子库和智能科技驱动的生物医药高科技企业。
公司致力于打造全球顶尖的原创新药创新工场。公司以智能超万亿分子库(AI-STAL)为核心;以干湿结合、国际领先的创新生物药智能化及一体化研发平台为依托;以多样化的业务模式推动全球创新药物的研发及产业化。
公司总部位于中国上海，在亚洲、北美洲、欧洲等多地建立了业务中心，形成了全球化的业务网络，现有投产及布局的研发及GMP场地20000多平方米。
公司已与全球2000多家药企、生技公司等建立了良好的合作关系，已赋能1200多个新药研发项目;已完成50多个合作研发项目，其中10多个协同研发项目已推至IND及临床研发阶段。
公司已申请130多项发明专利，其中30多项发明专利已获得授权，并获得了国家级高新技术企业、上海市专精特新、ISO9001、ISO27001等10余项资质及体系认证。
Sanyou Bio and Shanghai ZJ Bio-Tech Sign Strategic Cooperation Agreement on Automated Development of Innovative Biologics to Jointly Tackle R&D Bottlenecks and Provide New Momentum for Innovative Drug R&D
Shanghai, China – October 29, 2025 – Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter referred to as "Shanghai ZJ Bio-Tech") jointly announced the official signing of a strategic cooperation agreement on the automated development of innovative biologics. This collaboration aims to jointly tackle drug development bottlenecks by introducing automation technology to significantly shorten the R&D cycle for innovative drugs.
According to the agreement, Sanyou Bio will upgrade the development process through automation, substantially reducing the R&D timeline for innovative drugs. Through this strategic cooperation, Sanyou Bio will systematically upgrade its antibody drug molecule screening process, thereby freeing up scientific talent to focus more on creative work. Simultaneously, the more precise and stable automated processes will greatly enhance the efficiency of R&D budget utilization.
The significance of this strategic cooperation between Sanyou Bio and Shanghai ZJ Bio-Tech extends beyond "shortening the R&D cycle." It lies in enhancing the predictability and output efficiency of the R&D process, stimulating momentum for source innovation, and reshaping core corporate competitiveness through technological integration and strategic synergy. The collaborative outcomes will further advance the development of innovative antibody drugs and diagnostic/therapeutic technologies within the context of intelligent healthcare, ultimately benefiting patient populations globally.
Shanghai ZJ Bio-Tech and Sanyou Bio Sign Strategic Cooperation Agreement witnessed the signing ceremony
This cooperation will fully leverage Sanyou Bio's strengths in its globally leading AI-powered Super-Trillion Molecule Library (AI-STAL) technology, as well as intelligent drug screening and preclinical research. Combined with Shanghai ZJ Bio-Tech's automated smart system, the partnership is committed to significantly accelerating the drug development process.
Ms. Ni Weiqin, Deputy General Manager and Board Secretary of Shanghai ZJ Bio-Tech, and Dr. Lang Guojun, CEO of Sanyou Bio
Ms. Ni Weiqin, Deputy General Manager and Board Secretary of Shanghai ZJ Bio-Tech, stated:"We look forward to breaking down the barriers of traditional R&D models through this collaboration and jointly creating a new digital-intelligent paradigm for drug discovery that integrates 'automated hardware' and 'AI intelligent decision-making'. Our goal is not only to build the 'highway' for processes but also to achieve intelligent empowerment and paradigm innovation at the source stages, such as target discovery and molecular design, leveraging artificial intelligence and big data analytics. We aim to fully accelerate the translation of innovative drugs from the laboratory to the clinic, contributing technological power to the benefit of human health."
Dr. Lang Guojun, Founder and CEO of Sanyou Bio, said:"We are very pleased to formally establish this strategic cooperation with Shanghai ZJ Bio-Tech. This collaboration aims to address core challenges in biologics R&D through cutting-edge innovative approaches. By deeply integrating Sanyou's AI-STAL™ intelligent ultra-trillion molecular library with ZJ Bio-Tech's automation and intelligent technologies, we will jointly drive breakthroughs in key technologies for innovative biologics R&D. Leveraging our complementary strengths, we are committed to building a more efficient and intelligent R&D system, thereby significantly shortening drug development timelines and accelerating the launch of innovative therapies—bringing more timely treatment hope to patients worldwide."
The strategic cooperation includes joint research, technology transfer, and other aspects.
About Shanghai ZJ Bio-Tech
Shanghai ZJ Bio-Tech Co., Ltd. (Stock Code: 688317) is a national high-tech enterprise specializing in the R&D, production, and sales of molecular diagnostic reagents and instrument equipment. As a leading molecular diagnostic company in China, it boasts advanced technology and a comprehensive product portfolio. The company holds over 80 authorized patents and has received more than 10 major awards, including the second prize of the National Technology Invention Award. It has undertaken over 40 national and provincial-level major research projects. During global public health emergencies such as highly pathogenic avian influenza, Ebola virus, and Zika virus outbreaks, the company has made significant contributions. Multiple products have been included in the WHO Emergency Use Listing, receiving authoritative recognition.
About Sanyou Biopharmaceuticals
Sanyou Biopharmaceuticals is a high-tech biopharmaceutical enterprise driven by its super-trillion moleculelibrary and artificial intelligence technology, with the mission of “making innovative biologics R&D easy for clients worldwide”.
SanyouBio has been dedicated to developing a world-class innovative biological drug R&D hub. The company is centered on its AI-driven super-trillion antibody library (AI-STAL) and supported by its world-leading, integrated and intelligent R&D platform for innovative biologics development that seamlessly combines in silico and wet-lab capabilities. Sanyou drives the global development and industrialization of innovative new drugs through diversified business models.
Headquartered in Shanghai, China, Sanyou has established global business centers across Asia, North America, and Europe, forming an international business network. The company currently operates and has planned over 20,000 square meters of R&D and GMP facilities.
Sanyou has established strong collaborations with more than 2,000 pharmaceutical and biotech companies worldwide, empowering over 1,200 new drug discovery and development projects. It has completed more than 50collaboration projects, over 10 of which have advanced to IND approval and clinical development stages.
The company has filed over 130 invention patents, with more than 30 granted. It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai “Specialized and Innovative” Enterprise, ISO9001, and ISO27001.
评论排行